Il-15 Superagonist and Dinutuximab significantly Enhance Expanded Natural Killer Cell Activity Against Gd2(+) Pediatric Solid Tumors (ST)

Authors

Yaya Chu, New York Medical CollegeFollow
Gaurav Nayyar
Jeremy Rosenblum, New York Medical CollegeFollow
Jeremy Lyngdoh, New York Medical College
Jing Cao
Emily Jeng
Sarah AlterFollow
Peter R. Rhode
Salomon Amar, New York Medical CollegeFollow
Dean A. LeeFollow
Hing C. Wong
John H. LeeFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty, Student

Document Type

Abstract

Publication Date

6-2019

Journal Title

Pediatric Blood & Cancer

Department

Pediatrics

Second Department

Pharmacology

Recommended Citation

Chu, Y., Nayyar, G., Rosenblum, J., Lyngdoh, J., Cao, J., Jeng, E., Alter, S., Rhode, P. R., Amar, S., Lee, D. A., Wong, H. C., Lee, J. H., & Cairo, M. S. (2019). Il-15 Superagonist and Dinutuximab significantly Enhance Expanded Natural Killer Cell Activity Against Gd2(+) Pediatric Solid Tumors (ST). Pediatric Blood & Cancer, 66 (Suppl. 2), 1026. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/275